Navigation Links
Diet and lifestyle critical to recovery, says study
Date:1/17/2008

Diet and lifestyle may play a much more significant role in a persons ability to respond favourably to certain drugs, including some cancer therapies, than previously understood, say scientists.

Writing in Nature Genetics, University of Manchester researchers have shown how the nutrients in the environment are critical to the fitness of cells that carry genetic mutations caused by diseases.

The findings for the first time provide a scientific insight into why some people might respond better to certain medications than others and form the foundations for more individualised drug therapy in the future.

The team used bakers yeast a model organism studied by biologists to reveal molecular processes in higher organisms to explore the relationship between environment and genetic background.

The large-scale study involved removing one of the two copies of all yeast genes similar to removing one parents set of genes in a human and analysing the resulting fitness under different dietary restrictions.

If the gene targeted is quantitatively important, you would normally expect the yeast to show a reduction in fitness, said Dr Daniela Delneri, who carried out the research in the Universitys Faculty of Life Sciences.

But what we found was that in certain environmental conditions, removing one copy of certain genes actually produced the opposite effect and surprisingly the yeast cells grew more quickly and were healthier.

The team further established that this effect was mainly occurring in genes involved in the proteasome the quality-control system within the cell that degrades unwanted proteins.

The proteasome is important as it maintains the equilibrium of the cell, said Dr Delneri. When this equilibrium is lost it can result in a number of diseases, including cancer, diabetes, Huntingdons, Alzheimers and Parkinsons.

For example, in rapidly-growing cancerous cells the high proteasome activity renders the tumour cells immortal, so drugs that block or inhibit the proteasomes actions are currently used as therapeutic compounds.

Our study shows that reduced proteasome activity could be either advantageous or damaging to the cell depending on the nutrients available to it in the surrounding environment.

The findings suggest that, ideally, when therapeutic drugs are administered to alter the proteasome activity, the environment governed by the type of tissue or a persons diet and lifestyle should be taken into consideration to assure the correct beneficial effect.


'/>"/>

Contact: Aeron Haworth
aeron.haworth@manchester.ac.uk
44-161-275-8383
University of Manchester
Source:Eurekalert

Related biology news :

1. SAGEs American Journal of Lifestyle Medicine looks at the health benefit of oats
2. Critically endangered Amur leopard captured
3. First-ever study: lack of critical lubricant causes wear in joints
4. Rutgers scientists research reveals critical knowledge about the nervous system
5. Critically endangered porpoise is focus of new research report
6. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
7. A study by the MUHC and McGill University opens a new door to understanding cancer
8. Study begins to reveal clues to the cause and progression of sepsis
9. Clones on task serve greater good, evolutionary study shows
10. New study warns limited carbon market puts 20 percent of tropical forest at risk
11. New study examines how rearing environment can alter navigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 ... user experience and security for consumer electronics, and ... payment processing systems and cybersecurity solutions, today announced ... enterprises and financial institutions worldwide to bolster security ... the end-to-end secure user authentication platforms they offer, ...
(Date:1/18/2017)... Jan. 18, 2017 MedNet Solutions ... supports the entire spectrum of clinical research, is ... record-breaking year for the organization in terms of ... MedNet,s eClinical products and services. The company,s exceptional ... success of iMedNet ™ ...
(Date:1/12/2017)... SAN DIEGO , Jan. 12, 2017  Trovagene, ... circulating tumor DNA (ctDNA) technologies, today announced that it ... Europe and the Middle ... biopsy tests.  This milestone marks the first wave of ... tests for urine and blood samples. The ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... ... 2017 , ... The two newest companies to join the University City Science ... out from The Wistar Institute, and Sanguis, launched by a trio of students from ... , Vironika is developing a treatment for a chronic viral infection and its associated ...
(Date:1/19/2017)... Research and Markets has announced the addition of the "Cancer ... Opportunity Analysis and Industry Forecast, 2014-2022" report to their offering. ... Cancer Biomarkers ... $15,737 million by 2022 from $6,521 in 2015, growing at a ... technologies segment accounted for more than half of the revenue share ...
(Date:1/19/2017)... , ... January 19, 2017 ... ... advanced software solutions for pharmaceutical research and development (R&D), today announced the ... omic data analysis and interpretation for the rapidly evolving field of precision ...
(Date:1/19/2017)... ... January 18, 2017 , ... The American Medical Informatics Association ... Data Sharing Policy. Specifically, the nation’s leading informatics experts, said data sharing plans ... policy. AMIA recommended that NIH earmark funding for researchers to produce and execute ...
Breaking Biology Technology: